Showing: 1 - 2 of 2 RESULTS

Xellia Pharmaceuticals Launches New Doses of VANCO READYTM (Ready-to-use Room Temperature Premixed Vancomycin Injection Bags)

Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, is launching three new doses of VANCO READYTM, expanding its range of room temperature stable, ready-to-use (RTU) Vancomycin injection premix bags.

The VANCO READYTM availability will now cover all relevant doses from 500 mg to 2 g in 250 mg increments.

The availability of 750 mg in 150 mL, 1.25 g in 250 mL and 1.75 g in 350 mL are joining our range of presentations launched in 2019 – 500 mg in 100 mL, 1 g in 200 mL, 1.5 g in 300 mL and 2 g in 400 mL.

VANCO READYTM should not be administered during pregnancy, please see boxed warning below.

Carl-Åke Carlsson, Xellia’s CEO said: “With all seven VANCO READYTM presentations, Xellia can service the majority of needs of healthcare professionals in the vancomycin injection market. The success of our first four products has resulted in over 2,000 US institutions using VANCO READYTM. Since our announcement of approval, we have already seen strong interest and demand for the new codes from healthcare professionals on the basis of the product being room temperature and the most ready to use product available.”

Vancomycin Injection is a glycopeptide antibacterial indicated in adult and pediatric patients (1 month and older) for the treatment of septicemia (sepsis), infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections.

Craig Boyd, Xellia’s North American President said: “One of the uses for Vancomycin in the US is in the treatment of sepsis. The timely initiation of effective antibiotic treatments is universally recognized as a key intervention in the management of this life-threatening state as well as other infections. We are pleased to have been able to expand the range of doses available to clinicians, broadening their options to aid rapid and effective treatment.”

In the United States, sepsis is the third leading cause of death after heart disease and cancer, affecting more than 1.7 million people and killing more than 270,000 people within a single year1.

“Our room-temperature-stable VANCO READYTM premix has been critical in providing a truly ready Vancomycin Injection product. It aligns with recommendations from US agencies – such as the American Society of Hospital Pharmacists (ASHP), Institute for Safe Medication Practices (ISMP) and Joint Commission – to use manufacturer-prepared products as part of safe medication practice. We will continue to build on this success and focus on our ready-to-use product pipeline and partnerships during 2020.”

– Ends –


1 Rhee, C. et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 318, 1241–1249 (2017).

Full prescribing information for Vancomycin Injection Premix RTU can be found at and

About Vancomycin Injection

Vancomycin Injection, Ready to use (RTU) is a proprietary formulation of vancomycin, provided as a premixed solution in single-dose flexible bags, stable at room temperature (up to 25 °C) for 16

Injection of drug that promotes blood clotting could save accident victims

  • Tranexamic acid is a drug currently used to stop bleeding in trauma patients
  • At present it is administered via an intravenous line — which is fiddly to set up
  • British and French experts have shown it can be given like a ‘flu jab into muscle
  • The team are working on an EpiPen-like device for accident sites and warzones

The lives of thousands of accident victims could be saved by injecting a common drug that helps stop bleeding at the scene of the incident, a study has found.

Experts from the UK and France found that an injection of tranexamic acid reduces traumatic injury death rates by up to a third — if administered within an hour.  

The team proved that the drug can be successfully administer as an intramuscular injection — like a ‘flu jab — rather than the traditional intravenous line.

The finding may be of most benefit in low- and middle- income nations, the team said, where first responders are less likely to be trained to set up intravenous lines.

In fact, these countries see more that 90 per cent of the world’s trauma deaths — around 80 per cent of which occur before the patient even arrives at hospital.

The lives of thousands of accident victims could be saved by injecting a common drug that helps stop bleeding at the scene of the incident, a study has found (stock image)

‘Intramuscular tranexamic acid is like a vaccine against trauma death,’ paper author and epidemiologist Ian Roberts of the London School of Hygiene and Tropical Medicine told the Times.

‘An urgent injection of tranexamic acid is life-saving after serious injury. but patients are not being treated fast enough,’ he added.

‘A rapid intramuscular injection given by first responders or paramedics could mean the difference between life and death.’

Click here to resize this module

Tranexamic acid is already used to stabilise trauma patients — but it is traditionally administered by an intravenous line — which takes longer to set up and work.

‘At the moment in the NHS tranexamic acid is used but patients aren’t getting it quick enough. It’s most effective when given within an hour of injury, and the hours just disappear so quickly,’ Professor Roberts told the Times.

‘It takes time for the ambulance to arrive, time for paramedics to orientate themselves to what’s going on. It takes a little time to put in an intravenous line — sometimes they just say, well, let’s leave that for the hospital.’

‘This way, you can just inject it intramuscularly and forget about it.’

Every quarter-hour delay a patient experiences in getting tranexamic acid reduces the drug’s lifesaving potential by around 10 per cent, Professor Roberts explained — adding that only 3 per cent of UK trauma victims receive it within one hour. 

Experts from the UK and France found that an injection of tranexamic acid, pictured, reduces traumatic injury death rates by up to a third — if administered within an hour (stock image)

In their study,